A mutation on the BAP1 tumor suppressor gene can influence the development of malignant mesothelioma but may have little bearing on survival. That conclusion comes from a new Chinese study of more than 2,400 people with cancers directly linked to the BAP1 genetic mutation, including pleural mesothelioma. BAP1 and Mesothelioma BRCA1-associated protein 1 (BAP1) is a tumor suppressing protein encoded by the BAP1 gene. Multiple studies … Continue reading The Influence of BAP1 on Mesothelioma Survival
Researchers in Belgium say a breath analysis tool could provide the next big breakthrough in the effort to diagnose malignant mesothelioma earlier. The team, made up of scientists from Ghent and Antwerp Universities, says the technique looks “very promising” and fits well within the aims of the “National Cancer Moonshot” research initiative established by President Obama. The Challenge of Mesothelioma Diagnosis Malignant pleural mesothelioma (MPM) … Continue reading A Breath Test for Mesothelioma?
A calcium-binding protein called calretinin may provide the basis for a new kind of blood test for the asbestos-linked cancer, malignant mesothelioma. Right now, there is no reliable way to detect the presence of a mesothelioma tumor before symptoms develop. The Search for a Mesothelioma Blood Test But scientists around the world are searching for ways to use certain compounds produced by tumors to diagnose mesothelioma … Continue reading New Blood Test Could Mean Earlier Mesothelioma Diagnosis
New research suggests that a protein often used to help diagnose and track malignant mesothelioma may also be a valuable prognostic indicator. Soluble mesothelin-related protein (SMRP) is a biomarker for pleural mesothelioma, an aggressive asbestos-linked cancer that causes few symptoms until in its late stages. The presence of SMRP in the blood indicates that mesothelial cells on the lining around the lungs have been damaged. … Continue reading Predicting Mesothelioma Outcomes with Soluble Mesothelin
There is more evidence that a measure of how well the immune system is functioning may be an efficient prognostic tool for people with malignant pleural mesothelioma. Even though some recent studies have found the ratio of neutrophils to lymphocytes (NLR) in the blood to be a poor prognostic indicator for cancer, Chinese researchers say it may still be effective for planning mesothelioma treatment and qualifying … Continue reading More Evidence for Inflammation Marker in Mesothelioma Prognosis
A biomarker called soluble mesothelin related peptide (SMRP) may be a more reliable way to diagnose malignant pleural mesothelioma from lung fluid than the protein fibulin-3. That is the finding of Italian researchers who tested the diagnostic performance of the two markers in 120 patients, including 33 mesothelioma patients, in an effort to resolve what they call “conflicting data” on the two methods. SMRP and … Continue reading Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers
There is new evidence that the same genetic mutation that is common in people with pleural mesothelioma may be present in many cases of peritoneal mesothelioma, too. BAP1 is a tumor suppressing protein encoded by the BAP1 gene. People with a mutation in this gene are less likely to produce the protein and are more likely to develop certain kinds of cancer, including pleural mesothelioma. … Continue reading BAP1 May Be Valuable for Peritoneal Mesothelioma Prognosis
Mesothelioma patients with elevated levels of a particular enzyme in their blood prior to the start of mesothelioma treatment may not live as long as those with lower levels. Afters years of mixed messages from researchers on this topic, scientists in China believe they have finally confirmed the value of the enzyme lactate dehydrogenase (LDH) as a prognostic factor in malignant pleural mesothelioma. LDH has been … Continue reading Blood Test Could Aid in Mesothelioma Treatment Planning
There is more evidence this week that the tumor suppressor gene known as BRCA1-associated protein 1 (BAP1) could help doctors distinguish pleural mesothelioma from other types of lung cancer – even cancers that commonly spread to the pleura. Pleural mesothelioma is unique among cancers in that it starts on the pleural membrane that surrounds the lungs. When other types of cancers metastasize to this region, … Continue reading Gene Test May Help Distinguish Pleural Mesothelioma from Lung Cancer
A team of international researchers say they have identified a promising new biomarker for malignant pleural mesothelioma, a rare but deadly cancer caused by exposure to asbestos. A biomarker is a compound found in the tissue, blood or other body fluid that is produced in higher amounts when disease is present. In the case of a new report presented at the annual International Association for … Continue reading International Team Identifies Potential New Mesothelioma Biomarker
Get your free copy of
“Surviving Mesothelioma” Today!